ABSTRACT
INTRODUCTION

48
The PI3K/AKT/mTOR pathway is frequently dysregulated in human cancers by virtue of 49 a variety of molecular aberrations, including PIK3CA mutations, which are frequently found in 50 diverse cancers. [1] [2] [3] [4] [5] [6] [7] Preclinical models and early clinical data suggested that PIK3CA mutations 51 may predict sensitivity to treatment with PI3K/AKT/mTOR inhibitors in multiple tumor types. [8] [9] [10] [11] [12] [13] [14] 52
Patients with diverse tumors and PIK3CA mutations demonstrated a response rate of 53 35% in early phase clinical trials with PI3K/AKT/mTOR inhibitors compared to 6% in patients 54 without PIK3CA mutations.
11 It is, however, conceivable that only subsets of patients with 55
PIK3CA mutations derive benefit from therapy targeting the PI3K/AKT/mTOR pathway. 56
Resistance might be determined by the presence of simultaneous mutations in the mitogen 57 activated protein kinase (MAPK) pathway or by the type of PIK3CA mutation. An analogous 58 situation exists for EGFR mutations in non-small cell lung cancer (NSCLC), KIT mutations in 59 gastrointestinal stromal cancers and others, where differential sensitivity to targeting 60 compounds is of critical importance. 15, 16 . In the preclinical setting, PIK3CA mutation H1047R 61 was a stronger driver of tumor development than E545K or E542K and demonstrated sensitivity 62 to the mTOR inhibitor everolimus. 17 In addition, immortalized fibroblasts with the H1047R 63 PIK3CA mutation resulted in greater activation of AKT than E545K and E542K mutations. 18 
64
Finally, preclinical characterization of PWT33597, a dual inhibitor of PI3K and mTOR 65 demonstrated a lower IC50 for H1047R than E545K (86nM) or E542K (87nM) (21nM vs. 86 nM 66 and 87 nM, respectively).
19 Therefore, we investigated treatment outcomes with respect to the 67 type of PIK3CA mutation in patients with advanced cancer who were referred to the Clinical 68 Since January 2011, the assay has been changed to mass spectrometric detection (Sequenom 92 MassARRAY) to screen for the mutational hot spots in exon 1 (Q60K, R88Q, E110K and 93 K111N), exon 4 (N345K), exon 6 (S405S), exon 7 (E418K, C420R, E453K), exon 9 (P539R, 94 Assessments, including history, physical examination, and laboratory evaluations, were 110 performed as specified in each protocol, typically before the initiation of therapy, weekly during 111 the first cycle, and then, at a minimum, at the beginning of each new treatment cycle. Efficacy 112 was assessed from computed tomography (CT) scans and/or magnetic resonance imaging 113 (MRI) at baseline before treatment initiation and then every 2 cycles (6-8 weeks). All 114 radiographs were read in the Department of Radiology at MD Anderson and reviewed in the 115 Department of Investigational Cancer Therapeutics tumor measurement clinic. Responses were 116 categorized per RECIST 1.0 criteria. 21 In brief, complete response (CR) was defined as the 117 disappearance of all measurable and non-measurable disease; partial response (PR) was 118 defined as at least a 30% decrease in the sum of the longest diameter of measurable target 119 lesions; progressive disease (PD) was defined as at least a 20% increase in the sum of the 120 longest diameter of measurable target lesions, or unequivocal progression of a non-target 121 lesion, or the appearance of a new lesion; and stable disease (SD) was defined as neither 122 sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. 123
Statistical analysis 124
Two-way contingency tables were employed to summarize the relationship between two 125 categorical variables. Fisher's exact test was used to assess the association among categorical 126 variables and PIK3CA mutation status. A Wilcoxon rank-sum test was applied to assess the 127 association among continuous variables and PIK3CA mutation status. Multicovariable logistic 128 regression was applied to identify the multiple predictors associated with the response outcome 129 and number of prior therapies, histology, type of therapy, PIK3CA mutation types and KRAS 130 mutations, etc. Progression-free survival (PFS) was defined as the time interval from the start of 131 therapy to the first observation of disease progression or death, whichever occurred first. 132
Patients alive and without disease progression were censored at the last follow-up date. Overall 133 survival (OS) was defined as the time interval from the start of therapy to the date of death or 134 the date of last follow-up, whichever occurred first. OS and PFS were estimated using the 135 method of Kaplan and Meier and were compared among the subgroups of patients using a log-136 rank test. Cox proportional hazards regression models were fit to assess the association 137 between patient characteristics and PFS or OS. All tests were two-sided, and P values less than 138 0.05 were considered statistically significant. All statistical analyses were carried out using 139 SPSS 17 computer software (SPSS Chicago, IL PIK3CA were found in 67 (64%) patients, in exon 20 in 36 (34%) patients, and in other exons in 160 2 (2%) patients. The most frequent mutation was E545K (1633G>A) in 35 (33%) patients, 161
followed by H1047R (3140A>G) in 20 (19%) patients, and E542K (1624G>A) in 19 (18%) 162 patients ( Table 2) . 163
Of the 1,012 patients, 717 were tested for KRAS and 137 (19%) were found to have 164 mutations. The most prevalent was the G12D mutation (35G>A) present in 41 (30%) patients, 165 G12V mutation (35G>T) in 26 (19%), G13D mutation (38G>A) in 18 (13%), G12A mutation 166 (35G>C) in 12 (9%) patients, and G12C (34G>T) in 12 (9%) patients ( Of the 1,012 patients, 367 were tested for NRAS and 24 (7%) had mutations. The most 174 prevalent was the Q61R mutation (182A>G) present in 13 (54%) patients with a NRAS 175 mutation, Q61K mutation (181C>A) in 6 patients (25%), Q61L mutation (182A>T) in 3 patients 176 (13%), G12S mutation (34G>A) in 1 (4%) patient, and G13D (38G>A) in 1 (4%) patient. NRAS 177 mutations were not associated with PIK3CA mutations. 178
Of the 1,012 patients, 586 were tested for PTEN expression and 88 (15%) demonstrated 179 complete loss of staining. PTEN status was not associated with PIK3CA or KRAS mutation 180
status. 181
Patients with H1047R PIK3CA mutation respond to PI3K/AKT/mTOR inhibitors 182
Response rate 183
Of the 105 of patients with PIK3CA mutations 66 (63%) were prospectively enrolled in 184 clinical trials that included a PI3K/AKT/mTOR inhibitor. These patients were refractory to a 185 median of three prior therapies (range, 1 to 12). Of these 66 patients, 17 (26%) had colorectal 186 cancer, 12 (18%) breast cancer, 10 (15%) ovarian cancer, 9 (14%) endometrial cancer, 6 (9%) 187 squamous cell cervical cancer, 4 (6%) squamous cell head and neck cancer, 2 (3%) renal 188 cancer, and 6 (9%) other cancers (adenoid cystic head and neck cancer, anal squamous cell 189 cancer, appendiceal carcinoma, carcinoma of unknown primary, papillary thyroid cancer, and 190 small intestine cancer) (Figure 1 ). Most patients (52/66, 79%) received mTORC1 inhibitor 191 (rapalog) based therapy, 9 (14%) PI3K inhibitor based therapy, 3 (4%) dual PI3K and mTOR 192 kinase inhibitor based therapy, and 2 (3%) AKT inhibitor based therapy (Supplementary Table  193 1). Single-agent therapies were given to 28 (42%) patients and 38 (58%) received combination 194 CAN-12-1726 Of the 66 treated patients with PIK3CA mutations, 23 (35%) had available tissue for 220 NRAS testing and only 1 (4%) had the mutation. This patient had PD after 1.6 months. 221
Of the 66 treated patients with PIK3CA mutations, 32 (48%) had available tissue for 222 PTEN expression testing and 5 (16%) had a complete loss of staining. These five patients had 223 had SD ranging from 3.7 months to 4.4 months (n=2) or PD (n=3). 224
Of the other factors considered, patients with PIK3CA mutations treated with 225 combination therapies including a PI3K/AKT/mTOR inhibitor had a higher PR rate (11/38, 29% 226 vs. 0/28, 0%; p=0.002) and a higher rate of SD>6 months/PR (14/38, 37%, vs. 1/28, 4%; 227 p=0.002) than patients treated with PI3K/AKT/mTOR inhibitor monotherapies. Also, patients 228 with colorectal cancer and PIK3CA mutations had a trend toward having a lower PR rate (0/17, 229 0% vs. 11/49, 22%; p=0.05) and a lower rate of SD>6 months/PR (1/17, 6% vs. 14/49, 29%; 230 p=0.09) than patients with PIK3CA mutations and other histologies. There was a trend to a 231 higher PR rate (9/38, 24% vs. 2/28, 7%; p=0.10) and rate of SD>6 months/PR (12/38, 32% vs. 232 3/28, 11%; p=0.07) in patients PIK3CA mutations with up to 3 prior therapies compared to 233 patients with more than 3 prior therapies. Patients with PIK3CA mutations with mutation 234 analysis in primary tumor tissue had similar PR rates (7/39, 18% vs. 4/27, 15%; p=1.00) and 235 rates of SD>6 months/PR (10/39, 26% vs. 5/27, 19%; p=0.56) compared to patients with 236 mutation analysis done in tissue from metastatic sites. 237
Since most patients (52/66, 79%) received treatment with rapalogs, we performed a 238 separate analysis for this group and found that patients with a H1047R mutation compared to 239 other PIK3CA mutations had a strong trend to a higher rate of PR (6/14, 43% vs. 5/38, 13%; 240 p=0.05) and a higher rate of SD>6 months/PR (7/14, 50% vs. 7/38, 18%; p=0.026 showed that none of factors tested independently predicted prolonged PFS. 289
Overall survival 290
The median OS for all patients with PIK3CA mutations treated with PI3K/AKT/mTOR 291 inhibitors was 9.6 months (95% CI 7.1-12.1) and there were no significant differences among 292 PIK3CA mutation subtypes (H1047R, E545K, E542K) and KRAS mutation subtypes (codon 12 293 and 13). Also there was no difference in a median OS between combinations vs. monotherapies 294 and in patients with up to 3 prior treatment regimens compared to patients with more than 3 295 
DISCUSSION
319
In the current study, in heavily pretreated patients with PIK3CA mutations, the overall 320 SD>6 months/PR rate following PI3K/AKT/mTOR inhibitor treatment was 23% (with 17% of all 321 patients attaining a PR). It is known that EGFR inhibitors preferentially induce response in 322 NSCLC with certain EGFR mutations and, similarly, KIT inhibitors are preferentially active in 323 gastrointestinal stromal tumors only with specific KIT mutations. 15, 16 It is therefore plausible that 324 certain PIK3CA mutation types predict enhanced sensitivity to PI3K/AKT/mTOR inhibitors. 325
Alternatively, resistance might be driven by molecular aberrations in other relevant pathways. 326
Our group and others demonstrated that in colorectal and other cancers PIK3CA mutations 327 often coexist with KRAS mutations, and preclinical data suggested that having a concurrent 328 KRAS mutation might account for resistance to PI3K/AKT/mTOR pathway inhibitors. [8] [9] [10] [22] [23] [24] In 329 agreement with these previous reports, we found in this study that cancers with PIK3CA 330 mutations compared to wt PIK3CA have a higher prevalence of simultaneous KRAS mutations 331 (36% vs. 17%; p<0.001). That was mainly due to the prevalence of simultaneous KRAS 332 mutations in patients with PIK3CA exon 9 compared to prevalence of KRAS mutations in 333 patients without PIK3CA exon 9 mutations (40% vs. 17%; p<0.001. In contrast, PIK3CA exon 334 20 mutations were not statistically associated with simultaneous KRAS mutations (29% vs. 335 19%; p=0.16 In the current study, we also analyzed treatment outcomes (PR, PFS, OS) for patients 338 with the most frequent PIK3CA mutations such as E545K, E542K in exon 9 coding for the 339 helical domain and H1047R in exon 20 coding for the kinase domain, and we found that patients 340 with a PIK3CA H1047R mutation compared to patients with other PIK3CA mutations treated on 341 the same protocols had a higher PR rate (38% vs. 10%; p=0.018) and a trend towards having a 342 longer median PFS (5.7 months vs. 2 months; p=0.06). Similarly, patients with a PIK3CA 343 H1047R mutation compared to patients with wt PIK3CA treated on the same protocols had a 344 higher PR rate (38% vs. 13%; p=0.02); they did not, however, have a statistically significant 345 longer median PFS (5.7 months vs. 3.5 months; p=0.34). In addition, patients with PIK3CA 346 mutations and simultaneous KRAS mutations in codon 12 or 13 compared to patients with 347 PIK3CA mutations and wt KRAS or codon 61 KRAS mutations had a significantly lower PR rate 348 (0% vs. 23%; p=0.046). However, KRAS mutations in codon 12 or 13 were not confirmed as an 349 independent factor for a PR in multivariate analysis. These observations regarding the 350 cancer and PIK3CA mutations treated with a PI3K/AKT/mTOR inhibitor had a strong trend 358 toward having a lower PR rate compared to other cancers with PIK3CA mutations (0% vs. 22%; 359 p=0.05). This trend might be explained by the frequent presence of simultaneous KRAS 360 mutations and low prevalence of H1047R mutations in the patients with colorectal cancer. 22, 23 It 361 is also possible that PIK3CA mutations may have different roles in different histologies. A 362 similar phenomenon has been reported for BRAF mutations. A BRAF V600E mutation is highly 363 predictive for response to BRAF inhibitors in melanoma, but not in colorectal cancer. 25, 26 . 364
In our study, all PRs in PIK3CA mutant patients were observed when combination 365 therapies including a PI3K/AKT/mTOR inhibitor were used (29% vs. 0%; p=0.002; combination 366 therapy including a PI3K/AKT/mTOR inhibitor vs. single-agent PI3K/AKT/mTOR inhibitor). 367
However, combinations were used as frequently in the wt PIK3CA group, and the response rate 368 was significantly lower, suggesting that it is not the use of combinations in and of itself thatmediates response. The need for combination therapy, rather than treatment with single-agent 370 PI3K/AKT/mTOR inhibitors was not unexpected as patients with advanced cancer, including 371 those with PIK3CA mutations, are likely to have other driver aberrations as well. 9, 10, [27] [28] [29] [30] Further, 372 preclinical models demonstrated that breast cancer cell lines with PIK3CA mutations develop an 373 apoptotic response to the single agent BEZ235 PI3K inhibitor only in the presence of BIM 374 expression, whereas paclitaxel was similarly effective irrespective of BIM expression. 31 Also 375 PIK3CA mutations can increase the expression of other factors such as heregulin, which lead to 376 oncogenic pathway activation independent of PI3K.
29 Last but not least, single agent mTOR 377 inhibition with rapalogs or even with mTOR kinase inhibitors can lead to feedback activation of 378 AKT signaling. 27, 28 379 There are several limitations to our data.
32 First, this study was retrospective and not 380 randomized, and our findings need to be confirmed in a more controlled fashion. Second, the 381 number of patients treated with PI3K/AKT/mTOR inhibitors was relatively small. Third, the 382 treatments used and the patient population were heterogeneous, though this might also imply 383 that the relevance of H1047R is not limited to any one drug or histology. It remains plausible, 384
however, that among distinct histologies, PIK3CA mutations may or may not function in 385 precisely the same role (principal driver mutation vs. passenger mutation). Further studies are 386 needed to explore the relationship between different agents and sensitivity based on specific 387 mutations. Finally, improved response rates did not translate to improved survival, though the 388 relatively small number of patients might preclude definitive conclusions. 389
In summary, we have demonstrated that heavily pretreated patients with advanced 390 cancers who harbor a PIK3CA H1047R mutation may be more sensitive to therapeutic targeting 391 with PI3K/AKT/mTOR pathway inhibitors. In multicovariable analysis, having a PIK3CA 392 H1047R mutation was the only independent factor predicting a response. Therefore, the role of 393 PIK3CA H1047R mutations warrants further investigation in the setting of prospective controlled 394 trials with the application of targeted PI3K/AKT/mTOR inhibitors in the clinic. Author Manuscript Published OnlineFirst on October 12, 2012; DOI: 10.1158 /0008-5472.CAN-12-1726 
FIGURE LEGENDS
Figure 1: Waterfall plot shows best response for patients with PIK3CA mutations treated with PI3K/AKT/mTOR inhibitors. Of the 66 treated patients, 65 are depicted in the waterfall plot (one patient died of unrelated causes prior to her first restaging). A total of 11 PRs and 11 minor regressions less than PR were observed. The overall PR rate was 17%. Patients with a H1047R mutation (marked with *) had a PR rate of 37.5% (6/16 -denominator includes the patient, who is not depicted), whereas none of the patients with KRAS mutations in codons 12 and 13 (marked with #) had a PR. Two patients with KRAS mutation Q61H had a SD > 6 months and a PR, respectively (marked with ‡). 
